Immune markers for lung cancer prognosis after surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how your immune system markers might help predict your outlook after lung cancer surgery. It aims to see if certain immune signals can guide future treatment planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have non-small cell lung cancer and are scheduled for surgery to remove the tumor.
- After surgery, your cancer stage is IB (with a tumor larger than 4 cm or certain higher-risk features), IIA, IIB, or IIIB.
- You are in good physical condition (able to do daily activities without help).
- You have not had chemotherapy or radiation before surgery and do not have other active cancers or serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This study looks at changes in small molecules, genetic material, and other markers in the blood before and after lung cancer surgery. The goal is to develop a simple blood test to monitor patients over time and see if the cancer comes back.
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
This study looks for blood markers that can predict how well certain lung cancer treatments work before surgery. By joining, you help find a simple blood test to guide personalized care.
Hear when a new Lung Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.